{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFOX&page=4", "query": { "intervention": "FOLFOX", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 265, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFOX&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFOX&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T03:10:06.662Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB161734", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "INCA33890", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 710, "start_date": "2024-01-04", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06179160" }, { "nct_id": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "ABT-806", "type": "DRUG" }, { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard cytotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-20", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213289" }, { "nct_id": "NCT07500298", "title": "Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Phase 1", "SAR445877", "FOlfox6", "Bevacizimab", "First Line Treatment", "Metastatic Colorectal Cancer (CRC)", "Microsatellite Stable" ], "interventions": [ { "name": "SAR445877", "type": "DRUG" }, { "name": "FOLFOX6", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2026-05-20", "completion_date": "2032-12-27", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07500298" }, { "nct_id": "NCT03300609", "title": "5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Adenocarcinoma", "RAS Wild Type", "Stage III Colorectal Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-02-27", "completion_date": "2019-10-03", "has_results": false, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300609" }, { "nct_id": "NCT04751448", "title": "COLON-MD: Colon Cancer Longitudinal Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colon Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 11, "start_date": "2021-02-01", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04751448" }, { "nct_id": "NCT02839343", "title": "Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Borderline Resectable Adenocarcinoma of the Head of the Pancrease" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "surgery", "type": "PROCEDURE" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2016-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 154, "location_summary": "Mobile, Alabama • Antioch, California • Berkeley, California + 122 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02839343" }, { "nct_id": "NCT00613080", "title": "Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "resection", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2008-04", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 119, "location_summary": "Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Auburn", "state": "California" }, { "city": "Cameron Park", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00613080" }, { "nct_id": "NCT00479583", "title": "Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "BMS-690514 / FOLFIRI", "type": "DRUG" }, { "name": "BMS-690514 / FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2007-09", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2011-11-30", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00479583" }, { "nct_id": "NCT02022033", "title": "BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "FOLFOXA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-02-01", "completion_date": "2022-03-17", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02022033" }, { "nct_id": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2031, "start_date": "2016-10-12", "completion_date": "2024-06-06", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-18T03:10:06.662Z", "location_count": 27, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872116" } ] }